Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2009

Yip Dana, Le Maithao N, Chan Joseph L-K, Lee Jonathan H, Mehnert Janice A, Yudd Anthony, Kempf Jeffery, Shih Weichung J, Chen Suzie, Goydos James S

Abstract excerpt

PURPOSE: Ectopic expression of GRM1 in murine melanocytes results in transformation into a form of melanoma, and more than 60% of human melanoma samples tested ectopically express GRM1. Stimulation of this receptor in vitro results in up-regulation of activated extracellular signal-regulated kinase (ERK). Furthermore, a xenograft model of melanoma treated with riluzole, an oral GRM1 blocking agent, showed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caspase 3
Share to Excitatory Amino Acid Antagonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Extracellular Signal-Regulated MAP Kinases

Share to Fluorodeoxyglucose F18

Share to Ki-67 Antigen

Share to Oncogene Protein v-akt

Share to Positron-Emission Tomography

Share to Receptors, Metabotropic Glutamate

Source

Open in PubMed Open full text

Identifiers

PMID: 19458050
DOI: 10.1158/1078-0432.CCR-08-3303
PMCID: PMC2812866

Genes

GRM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma.PMID 19458050Read ↗

Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.Semantic proximity Read ↗

Riluzole is a radio‐sensitizing agent in an in vivo model of brain metastasis derived from <scp>GRM</scp>1 expressing human melanoma cellsSemantic proximity Read ↗

Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer.Semantic proximity Read ↗

Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development.Semantic proximity Read ↗

Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon.Semantic proximity Read ↗

Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells.Semantic proximity Read ↗

Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma.Semantic proximity Read ↗

Glutamate receptors: emerging players in melanomagenesis.Semantic proximity Read ↗

Metabotropic Glutamate Receptor-1 as a Novel Target for the Antiangiogenic Treatment of Breast CancerSemantic proximity Read ↗

Selected GRIN2A mutations in melanoma cause oncogenic effects that can be modulated by extracellular glutamate.Semantic proximity Read ↗

Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation.Semantic proximity Read ↗

Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.